ArticleEClinicalMedicine2026
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dapiglutide, a dual glucagon-like peptide (GLP)-1 and GLP-2 receptor agonist, is under clinical development for bodyweight reduction in obesity, capitalising on GLP-1 receptor-mediated food intake-reducing effect leading to bodyweight loss and GLP-2 receptor-mediated improvement of gut barrier function and anti-inflammatory properties. Methods: In this 12-week, investigator-initiated, phase IIa, proof-of-concept, double-blind, placebo-controlled trial in Denmark, adults (18-75 years) with obesity (BMI ≥30 kg/m Findings: Between April 27, 2023, and April 24, 2024, 54 adults living with obesity (63% women; mean bodyweight 101·3 kg; mean BMI 35·2 kg/m Interpretation: Dapiglutide (4 mg or 6 mg) for 12 weeks did not result in a statistically significant difference in bodyweight change compared with placebo in persons with obesity. The safety profile was favourable, and the findings support further investigation of higher doses in larger and longer studies to evaluate the weight-lowering potential of dapiglutide. Funding: Unrestricted grant from Zealand Pharma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.